ABVX (Abivax) Marketable Securities: $16.33 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABVX Abivax SA ABVX
10 GF Score
Price $135.01
! 1 Warning Sign
View Full Analysis

What is Abivax Marketable Securities?

Abivax ABVX -1.20% 10 Marketable Securities is $16.33 Mil as of Mar. 2026. GuruFocus rates ABVX with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Abivax's Marketable Securities for the quarter that ended in Mar. 2026 was $16.33 Mil.

Abivax's annual Marketable Securities declined from Dec. 2023 ($9.87 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($16.04 Mil).

Abivax  (NAS:ABVX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Abivax Marketable Securities Related Terms

Abivax Marketable Securities Historical Data

* Premium members only.

The historical data trend for Abivax's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax Marketable Securities Chart

Abivax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 9.87 0.00 16.04

Abivax Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 16.04 16.33
ABVX
10GF Score
Abivax SA ABVX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abivax Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $16.33 Mil mean?
Abivax (ABVX) has a Marketable Securities of $16.33 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Abivax and its competitors.
Is Abivax's Marketable Securities too high?
Abivax's current Marketable Securities is $16.33 Mil. Overall, Abivax has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Abivax's Marketable Securities compare to VRTX and REGN?
Abivax's Marketable Securities of $16.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Abivax and its competitors. Abivax's current Marketable Securities is $16.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abivax stock overvalued right now?
Abivax (ABVX) has a current Marketable Securities of $16.33 Mil. The current Marketable Securities is $16.33 Mil. Abivax's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Abivax (ABVX), the current Marketable Securities is $16.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abivax Business Description

Address 7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
10GF Score

Get the complete analysis for ABVX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$135.01
Price